Company Overview of Tris Pharma, Inc.
Tris Pharma, Inc., a specialty pharmaceutical company, engages in research, development, and manufacture of over-the-counter, Rx branded products, and specialty generic products in the United States. The company develops extended release formulations for products intended for children, elderly, and adults having difficulty swallowing pills and requiring multi-dose treatment. Its products pipeline includes products for various disease indications, such as cough and cold, pain management, and neurological disorders. The company also offers specialty generic products in immediate and extended release versions. Tris Pharma, Inc. offers its products in various dosage forms, such as package powder...
2033 Route 130
Brunswick Business Park
Monmouth Junction, NJ 08852
Founded in 2000
Key Executives for Tris Pharma, Inc.
Director of Finance and Controller
Vice President of Operations
President of Generic Pharmaceuticals Business
Chief Scientific Officer and Executive Vice President of R&D Including Regulatory Affairs
Compensation as of Fiscal Year 2013.
Tris Pharma, Inc. Key Developments
Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal(TM) ER (carbinoxamine maleate) Extended-Release Oral Suspension
Sep 4 13
Tris Pharma, Inc. and FSC Laboratories, Inc. announced the signing of a definitive licensing agreement for the commercialization of Karbinal(TM) ER (carbinoxamine maleate) Extended-release Oral Suspension 4 mg/5 ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up. Karbinal ER is expected to be available in pharmacies across the U.S. in time for the 2014 spring allergy season. Under the terms of the exclusive agreement, Tris will manufacture Karbinal ER using its proprietary OralXR+(TM) technology and FSC will market the drug. FSC will pay Tris up to $20 million in fixed and sales-related milestones, as well as a significant double-digit royalty on net sales.
Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
Jul 10 13
Tris Pharma announced that its generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution, the first-to-market generic equivalent of ProCentra(R), which is indicated for the treatment of attention deficit disorder with hyperactivity (ADHD) and narcolepsy. Manufactured at Tris' U.S. Food and Drug Administration (FDA)-inspected, facility in Monmouth Junction, NJ, Dextroamphetamine Sulfate Oral Solution is now available in the U.S. through wholesalers and distributors, as well as directly to the trade. Dextroamphetamine Sulfate Oral Solution was approved by the FDA on May 29, 2013.
Tris Pharma, Inc. Appoints Janet Penner as President of Generic Pharmaceuticals Business
Jun 20 13
Tris Pharma, Inc. announced that it has named Janet Penner as President of its new generic pharmaceuticals business. Most recently, Janet headed sales & marketing at CorePharma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|